Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s share price traded down 5.7% during trading on Friday . The stock traded as low as $10.47 and last traded at $10.47. 110,281 shares traded hands during trading, a decline of 86% from the average session volume of 779,801 shares. The stock had previously closed at $11.10.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on IMNM shares. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Finally, Stephens assumed coverage on Immunome in a research report on Friday, November 8th. They set an "overweight" rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $28.83.
Read Our Latest Stock Report on IMNM
Immunome Stock Performance
The business's 50 day moving average price is $12.01 and its two-hundred day moving average price is $13.20. The company has a market capitalization of $657.88 million, a price-to-earnings ratio of -1.30 and a beta of 1.83.
Insider Buying and Selling
In other Immunome news, CTO Philip Tsai acquired 21,000 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was bought at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Clay B. Siegall bought 66,057 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares in the company, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 102,862 shares of company stock valued at $978,045 over the last quarter. Corporate insiders own 8.60% of the company's stock.
Institutional Trading of Immunome
A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its holdings in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock valued at $359,000 after buying an additional 1,520 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Immunome by 4.1% during the third quarter. Lord Abbett & CO. LLC now owns 450,280 shares of the company's stock valued at $6,583,000 after purchasing an additional 17,566 shares during the last quarter. Barclays PLC boosted its position in shares of Immunome by 125.9% in the 3rd quarter. Barclays PLC now owns 105,886 shares of the company's stock valued at $1,547,000 after purchasing an additional 59,016 shares during the period. Geode Capital Management LLC boosted its position in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after purchasing an additional 144,557 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Immunome during the 3rd quarter worth about $363,000. 44.58% of the stock is currently owned by institutional investors.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Read More
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
